

RESEARCH ARTICLE

Open Access



# General Practitioners' vitamin K antagonist monitoring is associated with better blood pressure control in patients with hypertension – a cross-sectional database study

Sven Streit<sup>1\*</sup>, Vladimir Kaplan<sup>2</sup>, André Busato<sup>3\*</sup>, Sima Djalali<sup>3</sup>, Oliver Senn<sup>3</sup>, Damian N. Meli<sup>1</sup> and the FIRE study group

## Abstract

**Background:** Patients requiring anticoagulation suffer from comorbidities such as hypertension. On the occasion of INR monitoring, general practitioners (GPs) have the opportunity to control for blood pressure (BP). We aimed to evaluate the impact of Vitamin-K Antagonist (VKA) monitoring by GPs on BP control in patients with hypertension.

**Methods:** We cross-sectionally analyzed the database of the Swiss Family Medicine ICPC Research using Electronic Medical Records (FIRE) of 60 general practices in a primary care setting in Switzerland. This database includes 113,335 patients who visited their GP between 2009 and 2013. We identified patients with hypertension based on antihypertensive medication prescribed for  $\geq 6$  months. We compared patients with VKA for  $\geq 3$  months and patients without such treatment regarding BP control. We adjusted for age, sex, observation period, number of consultations and comorbidity.

**Results:** We identified 4,412 patients with hypertension and blood pressure recordings in the FIRE database. Among these, 569 (12.9 %) were on Phenprocoumon (VKA) and 3,843 (87.1 %) had no anticoagulation. Mean systolic and diastolic BP was significantly lower in the VKA group ( $130.6 \pm 14.9$  vs  $139.8 \pm 15.8$  and  $76.6 \pm 7.9$  vs  $81.3 \pm 9.3$  mm Hg) ( $p < 0.001$  for both). The difference remained after adjusting for possible confounders. Systolic and diastolic BP were significantly lower in the VKA group, reaching a mean difference of  $-8.4$  mm Hg (95 % CI  $-9.8$  to  $-7.0$  mm Hg) and  $-1.5$  mm Hg (95 % CI  $-2.3$  to  $-0.7$  mm Hg), respectively ( $p < 0.001$  for both).

**Conclusions:** In a large sample of hypertensive patients in Switzerland, VKA treatment was independently associated with better systolic and diastolic BP control. The observed effect could be due to better compliance with antihypertensive medication in patients treated with VKA. Therefore, we conclude to be aware of this possible benefit especially in patients with lower expected compliance and with multimorbidity.

**Keywords:** Anticoagulant agents, Blood pressure control, Primary care

## Background

In times of novel oral anticoagulants (NOACs) coagulation monitoring (International Normalized Ratio testing, INR) is no longer needed. In several studies, NOACs have been shown not to be inferior to VKAs in stroke prevention in patients with atrial fibrillation [1] and in the treatment of venous thromboembolism [2].

However, there are several reasons why General Practitioners (GPs) may hesitate to switch patients from VKA to NOAC if INR is in therapeutic range: the higher price of NOACs, the greater risk of gastrointestinal bleeding [3], being familiar with perioperative (bridging)-management, and lastly no validated strategies for bleeding complications.

In addition, patients requiring anticoagulation often suffer from significant co-morbidities such as hypertension, cardiovascular disease (CVD), diabetes or renal failure [4]. In many countries, the INR value is monitored by GPs [5]. On the occasion of INR monitoring, GPs

\* Correspondence: sven.streit@biham.unibe.ch

<sup>†</sup>Deceased

<sup>1</sup>Institute of Primary Health Care BIHAM, University of Bern, Gesellschaftsstrasse 49, 3012 Bern, Switzerland

Full list of author information is available at the end of the article

have the opportunity to provide additional care to patients, such as adjusting the dosage of antihypertensive drugs, giving smoking cessation advice or treating high cholesterol. Therefore, it could be assumed, that patients under VKA treatment and consequent INR monitoring receive more comprehensive care of their comorbidities than patients without VKA treatment due to a higher consultation rate. A similar, but possibly confounding effect has been shown in a large Danish cohort of hypertensive patients, where patients with co-morbidities, particularly patients with heart failure and CVD had a significantly better blood pressure (BP) control [6]. This may indicate that the quality of care increases with the number of conditions causing a higher consultation rate and thus closer care management.

In our study, we aimed to evaluate the specific impact of INR monitoring on BP control in primary care patients with hypertension. Taking into consideration that other chronic conditions needing periodical monitoring could alter observed effects, we also investigated if patients with comorbid diabetes would differ regarding BP control. We focused on diabetes for two reasons. First, it is a chronic disease commonly managed in primary care with internationally well accepted guidelines uniformly suggesting a regular recall of patients for the monitoring of blood sugar target values. Second, it is undisputed that diabetes itself is an indication for BP control. If INR monitoring had a specific impact on BP control, it could be assumed that the effect would also be observed in patients with comorbid diabetes.

## Methods

Primary care patients were identified from the Family medicine ICPC-Research using Electronic medical records (FIRE) project database. The FIRE project is an ongoing research project at the Institute of General Practice of the University of Zurich, Switzerland. Established in 2009, it provides the first and largest standardized collection of structured medical routine data from Swiss primary care. Details about the database structure are reported elsewhere [7]. In brief, the database covers reasons for encounter according to the ICPC-2 classification (International Classification of Primary Care 2) [8], patient demographics, vital signs, laboratory data and both type and dosage of prescribed medication according to Anatomical Therapeutic Chemical/Defined Daily Dose Classification (ATC/DDD) coding established by the WHO [9]. General practitioners participating in the FIRE project extract these data in an anonymized way from their electronic medical records and pool them centrally in the FIRE database aggregated by individual consultation dates.

In our study, we identified patients being treated for hypertension based on prescribed medication. Cases with

ATC coding specifying antihypertensive medication were detected following the concept of pharmaceutical cost groups (PCG) [10]. We included all patients with respective medication for  $\geq 6$  months, at least two consultations within one year from May 2009 to February 2013 and recorded BP measurements. Subsequently, we selected patients with VKA treatment (ATC coding) for  $\geq 3$  months and compared them to patients without such treatment regarding BP control. In Switzerland, INR monitoring is mainly done by GPs using a point-of-care device in order to review the prescription and adjust dosing of VKA during the same consultation. We controlled for potential confounders by performing a linear regression analysis adjusting for age, sex, observation period, number of consultations, chronic conditions, coronary heart disease, heart failure, atherosclerosis, obesity, and diabetes. Chronic conditions were defined by applying a set of specific ICPC-2 codes first described by O'Halloran *et al.* [11] and validated for the FIRE database [12]. Moreover, we identified patients with diabetes type two by prescribed medication (PCG).

Data were analysed using STATA release 13.1 StataCorp, College Station, TX.


According to current Swiss law on human research (Humanforschungsgesetz, HFG) retrospective cross-sectional analysis of anonymized medical routine data requires no approval by the regional ethics committee Zürich [13]. Patient records/informations were anonymized and de-identified prior to analysis.

## Results

Consultation data of 56,765 adult primary care patients with at least two consultations within one year between May 2009 and February 2013 were eligible (Flowchart in Fig. 1). 6,347 of these patients (11.2 %) had a diagnosis of hypertension according to their list of medication. 5,026 (79.2 %) had prescribed medication for hypertension  $\geq 6$  months. Out of the 5,026 patients, 4,432 (88.2 %) had records of BP measurements and included in our study. Among these 4,432, 569 (12.9 %) were treated with Phenprocoumon  $\geq 3$  months and were included in the VKA group; 3,843 (87.1 %) patients had no anticoagulant treatment and were used as controls.

Table 1 depicts the baseline characteristics of patients in the VKA and control groups. The two groups differed significantly in age, sex, number of consultations per year and number and type of chronic conditions. Patients on VKA were approximately nine years older, more likely to be female, had more chronic comorbidities and visited their GP almost twice as often as controls.

Regarding BP control, both mean systolic and diastolic blood pressure were significantly lower by 9.2 mm Hg (systolic) and 4.7 mm Hg (diastolic) in the VKA group



( $p < 0.01$  for both) (Table 1). Additionally, the proportion of patients with controlled BP within target range, defined as  $<140/90$  mm Hg, was significantly higher in the VKA group (74.9 % vs. 49.5 %,  $p < 0.01$ ).

Table 2 provides the mean differences of systolic and diastolic BP between groups after adjustment for age, sex, observation period, number of consultations, number of chronic conditions, coronary heart disease, heart failure, atherosclerosis, obesity, and diabetes. Again, both systolic and diastolic BP were significantly lower in the

VKA group, and patients in the VKA group were more likely to meet the BP target range of  $<140/90$  mm Hg, odds ratio 2.7 (95 % CI 2.2 – 3.4).

Differences were also observed between the subgroups of patients with comorbid diabetes ( $n = 644$ ) (Table 3). Mean systolic BP was significantly lower in the VKA group ( $-7.2$  mm Hg,  $p < 0.001$ ); mean diastolic BP was not significantly lower ( $-0.4$  mm Hg,  $p < 0.7$ ). Odds ratio for controlled BP  $<140/90$  mm Hg was 1.7 (95 % CI 1.0 – 2.8,  $p = 0.044$ ).

**Table 1** Baseline characteristics and blood pressure (BP) of 4,412 patients with hypertension with and without VKA Treatment

	VKA group n = 569	Control group n = 3,843	p-value**
Age, years (SD)	76.7 (10.0)	67.8 (13.8)	<0.01
Men, %	47.6	52.4	0.044
Consultations/year, n (SD)	10.9 (7.2)	6.6 (5.5)	<0.01
Chronic conditions, n (SD)	3.8 (2.5)	3.1 (2.3)	<0.01
Coronary heart disease, n (%)	45 (7.9)	224 (5.8)	0.053
Heart failure, n (%)	28 (4.9)	50 (1.3)	<0.01
Atherosclerosis, n (%)	28 (4.9)	80 (2.1)	<0.01
Obesity, n (%)	20 (3.5)	235 (6.1)	0.01
Diabetes, n (%)	87 (15.3)	557 (14.5)	0.62
Mean systolic BP, mm Hg (SD)	130.6 (14.9)	139.8 (15.8)	<0.01
Mean diastolic BP, mm Hg (SD)	76.6 (7.9)	81.3 (9.3)	<0.01
Patients with controlled* BP, %	74.9	49.4	<0.01

\*defined as blood pressure <140/90 mmHg

\*\*p-value: Results of univariate comparisons between groups based on unpaired t-test or Chi-square test as appropriate

## Discussion

The aim of the study was to evaluate the effect of INR monitoring on BP control in primary care patients with hypertension. The results suggest that the hypothesized effect exists and that it is clinically relevant. After adjustment for confounders, both systolic and diastolic BP were significantly lower in the VKA group by about 9 mm Hg and 2 mm Hg, respectively.

These findings lead to the question, ‘Which factor associated with INR monitoring could cause the effect?’ One explanation is that INR monitoring requires regular consultations with the GP, where INR values are available right within the same consultation due to a point-of-care device. Indeed, comparison showed that patients under VKA treatment had significantly more consultations per year with their GP than controls. However, in the multivariate analysis, we controlled for the number of consultations and the effect sustained. Similarly, we controlled for the number of chronic conditions, because one could argue that patients under VKA treatment are more likely to suffer from multiple chronic conditions which require regular monitoring and increase GPs’ awareness for

BP control. A very common chronic disease that could unfold such a confounding effect is diabetes. In fact, the prevalence of patients with diabetes was approximately 15 % in our study population and therefore in the expected range considering age and morbidity [14]. Moreover, previous studies have shown that the majority of patients with diabetes in Swiss primary care undergo regular BP measurement [15]. Apparently, GPs are aware of the necessity of BP control in patients with diabetes. So, we analyzed patients with comorbid diabetes separately. Again, a lower BP under VKA treatment was observed.

Another explanation is that VKA agents have an inherent BP lowering effect. For instance, animal experiments revealed that specific coumarin agents or compounds have a dose-dependent, BP lowering effect [16, 17]. However, Phenprocoumon is not among these. Moreover, if Phenprocoumon had a physical effect on BP, normotensive patients under VKA treatment would regularly suffer from hypotension. To conclude, we consider this explanation as rather implausible.

Another explanation for our findings is that INR monitoring promotes patients’ adherence to medical therapy

**Table 2** Adjusted difference in blood pressure of patients with hypertension with and without VKA Treatment

Patients included (n = 4,412)	VKA group vs. control group	
	Adjusted <sup>a</sup> mean difference (95 % CI)	p-value
Systolic BP (mm Hg)	-8.4 (-9.8 – -7.0)	<0.01
Diastolic BP (mm Hg)	-1.5 (-2.3 – -0.7)	<0.01
	Adjusted* Odds Ratio (95 % CI)	p-value
Controlled BP (<140/90 mm Hg)	2.7 (2.2 – 3.4)	<0.001

<sup>a</sup>adjusted for age, sex, observation period, number of consultations and number of chronic conditions, coronary heart disease, heart failure, atherosclerosis, obesity, diabetes

**Table 3** Adjusted difference in blood pressure of patients with hypertension and comorbid diabetes with and without VKA Treatment

Subgroup of patients with prescribed diabetes medication (n = 644)	VKA group vs. control group	
	Adjusted <sup>a</sup> mean difference (95 % CI)	p-value
Systolic BP (mm Hg)	-7.2 (-10.9 – -3.6)	<0.001
Diastolic BP (mm Hg)	-0.4 (-2.3 – 1.5)	0.68
Controlled BP (<140/90 mm Hg)	Adjusted <sup>a</sup> Odds Ratio (95 % CI)	
	1.7 (1.01 – 2.8)	0.044

<sup>a</sup>adjusted for age, sex, observation period, number of consultations, number of chronic conditions, coronary heart disease, heart failure, atherosclerosis, obesity, diabetes

and subsequently enhances the intake of antihypertensive medication more than other monitoring measures. If so, it would be interesting to investigate whether the effect could also be observed in patients who routinely receive INR measurement by different healthcare providers or who perform self-monitoring at home.

Our study has several limitations. Due to the design of our study, we can only speculate about causality between VKA treatment and better blood pressure control. We also did not measure compliance to VKA treatment directly because our dataset did not contain INR-values or time in therapeutic range. However, also after adjusting for several possible confounding factors, we still observed a strong association between VKA and lower blood pressure. However, there remains the possibility of residual confounding due to missing data on e.g. BMI and limitations due to undercoding for reasons for anticoagulation.

A major strength of our study is that it is based on the substantial FIRE database and consequently a large sample size. As in February 2013, the database contained records from 56,756 patients and led to the inclusion of 4,412 patients in this study. Moreover, our inclusion criteria were rather strict, defining hypertension as antihypertensive medication intake for at least six months. As newly induced treatments can cause great variations in blood pressure control, we ensured that patients at the beginning of antihypertensive treatment were excluded. Patients who had received VKA treatment for less than three months were also excluded, in order to avoid the inclusion of patients under short-term anticoagulation therapy after thrombosis. Therefore, data can be considered as representative.

A significant association between VKA treatment and BP control could be shown. Although, our study method is limited to a cross-sectional design and not qualified to prove causality, our findings are of special relevance for daily practice in primary care. In the light of an increasingly older and multimorbid population, new models of care are required that are tailored to the needs of chronically ill patients. Indeed, health services research has yielded several promising concepts, e.g. the Chronic

Care Model or the Patient-Centered Medical Home Model [18, 19]. However, the implementation of these concepts into primary care routine of European countries is challenging and still in the early stage of its development [20]. Meanwhile, regularly recurring processes of care such as INR monitoring in GP practices fill in the gap and constitute an important opportunity for GPs to structure care provision, evolve a stable physician-patient-relationship and provide comprehensive medical care. Our findings show the importance of this «gap filling» and highlight that VKA should not be simply replaced by NOACs without a thorough implementation of new care models.

Further research is needed, in order to clarify which aspect of INR monitoring is causative for the observed BP lowering effect and how it could be systematically exploited, particularly in multimorbid patients.

## Conclusions

In a large sample of hypertensive patients in Switzerland, Vitamin-K antagonist treatment was associated with better systolic and diastolic BP control even after adjusting for several covariates such as comorbidities and number of consultations. The observed effect could be due to better compliance with antihypertensive medication in patients treated with VKA. Therefore, we conclude to be aware of this possible benefit especially in patients with lower expected compliance and with multimorbidity.

## Competing interest

The authors declare that they have no competing interest.

## Authors' contributions

SS was involved in conception and design of the study, interpretation of the data and drafting the manuscript. VK was involved in data management, statistics and interpretation of the data. AB led the data extraction from the FIRE database. SD was involved in data extraction from the FIRE database and drafting the manuscript. OS was involved in conception and design of the study, analysis and interpretation of the data and drafting the manuscript. DNM was involved in conception and design of the study, analysis and interpretation of the data and drafting the manuscript. All authors, except AB, who unfortunately deceased recently, gave approval to the final version of the manuscript.



# Acknowledgement

We thank the FIRE study group of general practitioners contributing to the present study.

# Author details

<sup>1</sup>Institute of Primary Health Care BIHAM, University of Bern, Gesellschaftsstrasse 49, 3012 Bern, Switzerland. <sup>2</sup>District Hospital Freiamt Muri, Muri, Switzerland. <sup>3</sup>Institute of General Practice, University of Zurich, University Hospital Zurich, Zurich, Switzerland.

Received: 9 February 2015 Accepted: 1 June 2015

Published online: 10 June 2015

# References

1. Ru San T, Chan MY, Wee Siong T, Kok Foo T, Kheng Siang N, Lee SH, et al. Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. *Thrombosis*. 2012;2012:108983.
2. Vanassche T, Verhamme P. Rivaroxaban for the treatment of pulmonary embolism. *Advances in therapy*. 2013;30(6):589–606.
3. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. *Gastroenterology*. 2013;145(1):105–12. e15.
4. LaMori JC, Mody SH, Gross HJ, DaCosta DiBonaventura M, Patel AA, Schein JR, et al. Burden of comorbidities among patients with atrial fibrillation. *Therapeutic Advances in Cardiovascular Disease*. 2013;7(2):53–62.
5. Streit S, Roberts R, Burman RA, Meli DN. Anticoagulation in primary care - a cross sectional study in 14 heterogeneous countries. *Cardiovascular Medicine*. 2013;16(11):299–302.
6. Paulsen MS, Andersen M, Thomsen JL, Schroll H, Larsen PV, Lykkegaard J, et al. Multimorbidity and blood pressure control in 37 651 hypertensive patients from Danish general practice. *Journal of the American Heart Association*. 2013;2(1):e004531.
7. Chmiel C, Bhend H, Senn O, Zoller M, Rosemann T, study-group F. The FIRE project: a milestone for research in primary care in Switzerland. *Swiss medical weekly*. 2011;140:w13142.
8. WONCA. ICPC-2-R: International Classification of Primary Care. 2nd ed. USA: Oxford University Press; 2005.
9. WHO Collaborating Centre for Drug Statistics Methodology: Guidelines for ATC classification and DDD assignment 2012. 15th ed. Oslo, 2011
10. Lamers LM, van Vliet RJA. The pharmacy-based Cost Group model: validating and adjusting the classification of medications for chronic conditions to the Dutch situation. *Health Policy*. 2004;68:113–21.
11. O'Halloran J, Miller GC, Britt H. Defining chronic conditions for primary care with ICPC-2. *Family Practice*. 2004;21:381–6.
12. Rizza A, Kaplan V, Senn O, Rosemann T, Bhend H, Tandjung R, et al. Age- and gender-related prevalence of multimorbidity in primary care: the Swiss FIRE project. *BMC family practice*. 2012;13:113.
13. Bundesamt für Gesundheit (BAG): Bundesgesetz über die Forschung am Menschen (Humanforschungsgesetz, HFG). 2011; <http://www.bag.admin.ch/themen/medizin/00701/00702/07558/>; Accessed February 7th 2015
14. Federation ID: IDF Diabetes Atlas 6th edition. 2013; <http://www.idf.org/diabetesatlas>; Accessed February 7th, 2015
15. Djalali S, Frei A, Tandjung R, Baltensperger A, Rosemann T. Swiss quality and outcomes framework: quality indicators for diabetes management in swiss primary care based on electronic medical records. *Gerontology*. 2014;60:263–73.
16. Imenshahidi M, Eghbal M, Sahebkar A, Iranshahi M. Hypotensive activity of auraptene, a monoterpene coumarin from *Citrus* spp. *Pharmaceutical biology*. 2013;51:545–9.
17. Ogawa H, Sasai N, Kamisako T, Baba K. Effects of osthonol on blood pressure and lipid metabolism in stroke-prone spontaneously hypertensive rats. *Journal of ethnopharmacology*. 2007;112:26–31.
18. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. *Milbank Q*. 1996;74:511–44.
19. American Academy of Family Physicians (AAFP), American Academy of Pediatrics (AAP), American College of Physicians (ACP), American Osteopathic Association (AOA): Joint Principles of the Patient-Centered Medical Home. 2007; [http://www.aafp.org/dam/AAFP/documents/practice\\_management/pcmh/initiatives/PCMHJoint.pdf](http://www.aafp.org/dam/AAFP/documents/practice_management/pcmh/initiatives/PCMHJoint.pdf); Accessed 07 May 2015
20. Elissen A, Nolte E, Knai C, et al. Is Europe putting theory into practice? a qualitative study of the level of self-management support in chronic care management approaches. *BMC Health Serv Res*. 2013;13:117.

**Submit your next manuscript to BioMed Central and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

